The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
Stay Connected. Manage Your Care.
Access your health information anytime and anywhere, at home or on the go, with MyHealth.
- Message your clinic
- View your lab results
- Schedule your next appointment
- Pay your bill
The MyHealth mobile app from Stanford Health Care puts all your health information at your fingertips and makes managing your health care simple and quick.
Guest Services
24/7
We are available to assist you whenever you need it. Give us a call at 650-498-3333 or GuestServices@stanfordmed.org.
PHYSICIAN HELPLINE
Have a question? We're here to help!
Call 1-866-742-4811
Monday - Friday, 8 a.m. - 5 p.m.
REFER A PATIENT
Fax 650-320-9443
Track your patients' progress and communicate with Stanford providers conveniently and securely.
Oliver Dorigo, M.D., Ph.D.
Gynecologic oncologist, Medical oncologist
Associate Professor of Obstetrics and Gynecology (Oncology) at the Stanford University Medical Center
- 875 Blake Wilbur Drive
- Palo Alto, CA 94304
- Phone: 650-498-6000
- 900 Blake Wilbur Drive
- Palo Alto, CA 94304
- Phone: 650-498-6004
- 900 Blake Wilbur Drive
- Palo Alto, CA 94304
- Phone: 650-498-6004
- 900 Blake Wilbur Drive
- Palo Alto, CA 94304
- Phone: 650-725-6079
Conditions Treated
Professional Overview
Professional Education
Board Certification: Gynecologic Oncology, American Board of Obstetrics and Gynecology (2008)
Board Certification: Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (2006)
Fellowship: UCLA School of Medicine (2005) CA
PhD, University of California, Los Angeles, Molecular Biology (2003)
Residency: UCLA School of Medicine (1999) CA
Residency: Ludwig Maximillians University (1992) Germany
Medical Education: University Heidelberg (1989) Germany
Honors & Awards
OB/GYN Resident Teaching Award, University of California, Los Angeles (2008)
STOP Cancer Career Development Award, STOP Cancer (2008)
Teaching Award, National Council on Resident Education in Obstetrics and Gynecology (2007)
Outstanding Podium Presentation Award, National Gynecologic Oncology Fellow’s Forum (2004)
American Association of Cancer Research Outstanding Poster Award, Toronto, Canada, American Association of Cancer Research, Toronto, Canada (1995)
Administrative Appointments
Director, Stanford Obstetrics and Gynecology, Division of Gynecologic Oncology (2013 - Present)
Director, Stanford Gynecologic Oncology Clinical Care Program (2013 - Present)
Patient Ratings and Comments
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Publications
Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease
Karam, A., & Dorigo, O. (2014). Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease. BRITISH JOURNAL OF DERMATOLOGY, 170(3), 661-671.
Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy.
Masghati, S., Nosratian, M., & Dorigo, O. (2014). Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy. Obstetrics and gynecology, 123(2), 433-435.
MMPs in Ovarian Cancer as Therapeutic Targets
Karam, A., & Dorigo, O. (2012). MMPs in Ovarian Cancer as Therapeutic Targets. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 12(7), 764-772.
Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm
Stoll, L. M., Parvataneni, R., Johnson, M. W., Gui, D., Dorigo, O., & Sullivan, P. (2012). Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm. HUMAN PATHOLOGY, 43(8), 1339-1343.
Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development
Sullivan, P. S., Maresh, E. L., Seligson, D. B., Habeeb, O., Wadehra, M., & Dorigo, O. (2012). Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development. MODERN PATHOLOGY, 25(8), 1140-1148.
Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells
Sharma, S., Santiskulvong, C., Bentolila, L. A., Rao, J., Dorigo, O., & Gimzewski, J. K. (2012). Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 8(5), 757-766.
Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease
Karam, A., & Dorigo, O. (2012). Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease. GYNECOLOGIC ONCOLOGY, 125(2), 346-351.
Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy
Penner, K. R., Dorigo, O., Aoyama, C., Ostrzega, N., Balzer, B. L., & Holschneider, C. H. (2012). Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. GYNECOLOGIC ONCOLOGY, 124(3), 542-548.
Effect of PI3K/Akt Pathway Inhibition-Mediated G(1) Arrest on Chemosensitization in Ovarian Cancer Cells
Fekete, M., Santiskulvong, C., Eng, C., & Dorigo, O. (2012). Effect of PI3K/Akt Pathway Inhibition-Mediated G(1) Arrest on Chemosensitization in Ovarian Cancer Cells. ANTICANCER RESEARCH, 32(2), 445-452.
Personalizing CA125 Levels for Ovarian Cancer Screening
Dorigo, O., & Berek, J. S. (2011). Personalizing CA125 Levels for Ovarian Cancer Screening. CANCER PREVENTION RESEARCH, 4(9), 1356-1359.
Cisplatin and PI3kinase Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells and Regulate Matrix-Metalloproteinase Expression
Karam, A. K., Santiskulvong, C., Fekete, M., Zabih, S., Eng, C., & Dorigo, O. (2010). Cisplatin and PI3kinase Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells and Regulate Matrix-Metalloproteinase Expression. CYTOSKELETON, 67(8), 535-544.
Robust In Vivo Transduction of a Genetically Stable Epstein-Barr Virus Episome to Hepatocytes in Mice by a Hybrid Viral Vector
Gallaher, S. D., Gil, J. S., Dorigo, O., & Berk, A. J. (2009). Robust In Vivo Transduction of a Genetically Stable Epstein-Barr Virus Episome to Hepatocytes in Mice by a Hybrid Viral Vector. JOURNAL OF VIROLOGY, 83(7), 3249-3257.
Dual targeting of mammalian target of rapamycin and phosphoinositide 3-kinase using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma
Dorigo, O., Santiskulvong, C., Fekete, M., Karam, A., Mulholland, D., & Wu, H. (2009). Dual targeting of mammalian target of rapamycin and phosphoinositide 3-kinase using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. GYNECOLOGIC ONCOLOGY, 112(2), S9-S10.
Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient
Lipshutz, G. S., Mihara, N., Wong, R., Wallace, W. D., Allen-Auerbach, M., & Pham, P.-T. T. (2009). Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient. AMERICAN JOURNAL OF TRANSPLANTATION, 9(2), 428-432.
HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review
Karam, A., Berek, J. S., Stenson, A., Rao, J., & Dorigo, O. (2008). HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. GYNECOLOGIC ONCOLOGY, 111(3), 568-571.
CA125: Megadaltons of novel opportunities
Dorigo, O., & Berek, J. S. (2007). CA125: Megadaltons of novel opportunities. GYNECOLOGIC ONCOLOGY, 104(3), 505-507.
Enhanced Expression of L9'S Mutant nAChR in Adult Mice Increases the Loss of Midbrain Dopaminergic Neurons
Schwarz, J., Schwarz, S. C., Dorigo, O., Labarca, C., Deshpande, P., & Lester, H. A. (2006). Enhanced Expression of L9'S Mutant nAChR in Adult Mice Increases the Loss of Midbrain Dopaminergic Neurons. The Journal of the Federation of American Societies for Experimental Biology, (20 (7)).
Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells
Dorigo, O., Gil, J. S., Gallaher, S. D., Tan, B. T., Castro, M. G., & Berk, A. J. (2004). Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. JOURNAL OF VIROLOGY, 78(12), 6556-6566.
Enhanced expression of L9'S mutant alpha 4 nAChR in adult mice increases the loss of midbrain dopaminergic neurons
Schwarz, S. C., Dorigo, O., Labarca, C., Berk, A. J., Lester, H. A., & Schwarz, J. (2004). Enhanced expression of L9'S mutant alpha 4 nAChR in adult mice increases the loss of midbrain dopaminergic neurons. MOVEMENT DISORDERS, 19, S42-S42.
Specific keynote: Immunological therapy for ovarian cancer
Berek, J. S., Dorigo, O., Schultes, B., & Nicodemus, C. (2003). Specific keynote: Immunological therapy for ovarian cancer. GYNECOLOGIC ONCOLOGY, 88(1), S105-S109.
Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine
Shawler, D. L., Bartholomew, R. M., Garrett, M. A., Trauger, R. J., Dorigo, O., & SOBOL, R. E. (2002). Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 129(1), 99-106.
A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature
Ghosh, K., Dorigo, O., Bristow, R., & Berek, J. (2000). A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 191(2), 212-215.
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile
Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., & Parker, S. E. (1999). IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. JOURNAL OF IMMUNOLOGY, 163(12), 6378-6385.
Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function
Dorigo, O., Turla, S. T., Lebedeva, S., & Gjerset, R. A. (1998). Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. JOURNAL OF NEUROSURGERY, 88(3), 535-540.
Gene therapy for ovarian cancer – Molecular scissors of the new millenium?
Dorigo, O., & Berek, J. S. (1998). Gene therapy for ovarian cancer – Molecular scissors of the new millenium?. Journal of Gynecologic Techniques, 4.
Synergy of transforming growth factor beta (TGF-beta) antisense and IL-2 gene therapy in the murine ovarian teratoma model
Dorigo, O., Shawler, D. L., Royston, I., Sobol, R. E., Berek, J. S., & Fakhrai, H. (1998). Synergy of transforming growth factor beta (TGF-beta) antisense and IL-2 gene therapy in the murine ovarian teratoma model. Gynecologic Oncology, (71).
Construction and characterization of retroviral vectors for interleukin-2 gene therapy
Fakhrai, H., Shawler, D. L., VANBEVEREN, C., Lin, H., Dorigo, O., & SOBOL, R. E. (1997). Construction and characterization of retroviral vectors for interleukin-2 gene therapy. JOURNAL OF IMMUNOTHERAPY, 20(6), 437-448.
Progress and prospects in vaccine therapy for gynecologic cancers.
Gurski, K. J., & Steller, M. A. (1997). Progress and prospects in vaccine therapy for gynecologic cancers. Oncology (Williston Park, N.Y.), 11(11), 1727-?.
Interleukin-2 (IL-2) gene therapy with allogenic fibroblasts in the CT-26 model of murine colorectal carcinoma
Shawler, D. L., Dorigo, O., Van Beveren, C., Bartholomew, R. M., Fakhrai, H., & Sobol, R. E. (1997). Interleukin-2 (IL-2) gene therapy with allogenic fibroblasts in the CT-26 model of murine colorectal carcinoma. Oncology Reports, 4(N1).
Gene therapy for ovarian cancer: Development of novel treatment strategies
Dorigo, O., & Berek, J. S. (1997). Gene therapy for ovarian cancer: Development of novel treatment strategies. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 7(1), 1-13.
Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., MERCOLA, D., & SOBOL, R. E. (1996). Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 93(7), 2909-2914.
Immuno-gene therapy of colon carcinoma and central nervous tumors
Sobol, R. E., Fakhrai, H., Shawler, D. L., Dorigo, O., Gjerset, R. A., & Bartholomew, R. (1996). Immuno-gene therapy of colon carcinoma and central nervous tumors. In: Gene Therapy and Cancer.
COMPARISON OF GENE-THERAPY WITH INTERLEUKIN-2 GENE MODIFIED FIBROBLASTS AND TUMOR-CELLS IN THE MURINE CT-26 MODEL OF COLORECTAL-CARCINOMA
Shawler, D. L., Dorigo, O., Gjerset, R. A., Royston, I., SOBOL, R. E., & Fakhrai, H. (1995). COMPARISON OF GENE-THERAPY WITH INTERLEUKIN-2 GENE MODIFIED FIBROBLASTS AND TUMOR-CELLS IN THE MURINE CT-26 MODEL OF COLORECTAL-CARCINOMA. JOURNAL OF IMMUNOTHERAPY, 17(4), 201-208.
INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA
SOBOL, R. E., Fakhrai, H., Shawler, D., GJERSET, R., Dorigo, O., & Royston, I. (1995). INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA. GENE THERAPY, 2(2), 164-167.
CHARACTERIZATION OF A NEW HUMAN GLIOBLASTOMA CELL-LINE THAT EXPRESSES MUTANT P53 AND LACKS ACTIVATION OF THE PDGF PATHWAY
Gjerset, R. A., Fakhrai, H., Shawler, D. L., Turla, S., Dorigo, O., & SOBOL, R. E. (1995). CHARACTERIZATION OF A NEW HUMAN GLIOBLASTOMA CELL-LINE THAT EXPRESSES MUTANT P53 AND LACKS ACTIVATION OF THE PDGF PATHWAY. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 31(3), 207-214.
INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR-CELLS AND FIBROBLASTS GENETICALLY-MODIFIED TO SECRETE INTERLEUKIN-2 (IL-2) - A PHASE-I STUDY
SOBOL, R. E., Royston, I., Fakhrai, H., Shawler, D. L., Carson, C., & Wilson, D. (1995). INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR-CELLS AND FIBROBLASTS GENETICALLY-MODIFIED TO SECRETE INTERLEUKIN-2 (IL-2) - A PHASE-I STUDY. HUMAN GENE THERAPY, 6(2), 195-204.
Apoptosis of CD4+ and CD8+ cells from HIV-1 infected individuals: role of anti-idiotypic antibodies
Muller, S., Brams, P., Collins, H., Dorigo, O., & Kohler, H. (1995). Apoptosis of CD4+ and CD8+ cells from HIV-1 infected individuals: role of anti-idiotypic antibodies. Vaccine Research, Vol 4(No 4).
VALUE OF BOWEL RESECTION AND PREOPERATIVE COLOSCOPY IN OVARIAN-CANCER
Dorigo, O., Meier, W., Scheidel, P., & Hepp, H. (1993). VALUE OF BOWEL RESECTION AND PREOPERATIVE COLOSCOPY IN OVARIAN-CANCER. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 254(1-4), 966-968.
LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNANT-TUMORS IN CORRELATION WITH KNOWN PROGNOSTIC FACTORS AND AS DISEASE PARAMETERS DURING CYTOKINE THERAPY
ROMISCH, M., Bauer, F., Daponte, A., Meier, W., Dorigo, O., & Eiermann, W. (1993). LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNANT-TUMORS IN CORRELATION WITH KNOWN PROGNOSTIC FACTORS AND AS DISEASE PARAMETERS DURING CYTOKINE THERAPY. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 254(1-4), 1091-1093.
ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM
Tillmanns, H., Neumann, F. J., Tiefenbacher, C., Dorigo, O., Parekh, N., & Kuebler, W. (1993). ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM. EUROPEAN HEART JOURNAL, 14, 82-86.
A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNANCIES IN AIDS
Herndier, B., McGrath, M., Abbey, N., Wang, H. T., Ng, V., & Kohler, H. (1993). A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNANCIES IN AIDS. HYBRIDOMA, 12(5), 529-537.
A MONOCLONAL-ANTIBODY (IF7) SPECIFIC FOR HUMAN ANTI-HIV IG INDUCES APOPTOSIS AND INHIBITS CTL ACTIVITY IN CD8+ LYMPHOCYTES FROM HIV-1 INFECTED INDIVIDUALS
Muller, S., Collins, H., Brams, P., Wang, H., Dorigo, O., & Kohler, H. (1993). A MONOCLONAL-ANTIBODY (IF7) SPECIFIC FOR HUMAN ANTI-HIV IG INDUCES APOPTOSIS AND INHIBITS CTL ACTIVITY IN CD8+ LYMPHOCYTES FROM HIV-1 INFECTED INDIVIDUALS. JOURNAL OF CELLULAR BIOCHEMISTRY, 68-68.
NEW TECHNIQUES FOR THE STUDY OF THE CORONARY MICROCIRCULATION - IMPORTANCE OF MEASUREMENTS OF CORONARY FLOW RESERVE IN THE CLINICAL SETTING
Tillmanns, H., Neumann, F. J., Waas, W., Mall, G., Parekh, N., & Kubler, W. (1992). NEW TECHNIQUES FOR THE STUDY OF THE CORONARY MICROCIRCULATION - IMPORTANCE OF MEASUREMENTS OF CORONARY FLOW RESERVE IN THE CLINICAL SETTING. CORONARY ARTERY DISEASE, 3(7), 586-592.
SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS-THAN 1750-G BORN TO MOTHERS WITH HELLP SYNDROME
Gortner, L., Pohlandt, F., Bartmann, P., Terinde, R., Versmold, H., & Dorigo, O. (1992). SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS-THAN 1750-G BORN TO MOTHERS WITH HELLP SYNDROME. JOURNAL OF PERINATAL MEDICINE, 20(1), 25-28.
PHARMACOLOGICAL EFFECTS ON CORONARY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA
Tillmanns, H., Neumann, F. J., Parekh, N., Dorigo, O., Tiefenbacher, C., & Kubler, W. (1990). PHARMACOLOGICAL EFFECTS ON CORONARY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA. EUROPEAN HEART JOURNAL, 11, 10-15.
MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART
Tillmanns, H., Neumann, F. J., Parekh, N., Zimmermann, R., Tiefenbacher, C., & Kubler, W. (1990). MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 39, S9-S12.
Patient Comments
9 Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, Nov 2014
Dr. Dorigo is an excellent doctor. I like the way he treats me as a patient.
SHC Patient, Oct 2014
I love him.
SHC Patient, Oct 2014
I liked that both Dr. Dorigo and his nurse called the next day after surgery to check on my well-being.
SHC Patient, Sep 2014
Dr. Dorigo is the most caring and intelligent doctor I encountered throughout my cancer journey. He is the biggest blessing to me throughout this journey!
SHC Patient, May 2014
Dr. Oliver Dorigo went above and beyond with patience and understanding with me as I completely emotionally, fell apart after my diagnosis. He took more time than he should have.
SHC Patient, Apr 2014
Good experience.
SHC Patient, Mar 2014
I did my "homework" on Dr. Dorigo before my appointment and was impressed but once I met him - I knew I was in excellent "hands".
SHC Patient, Feb 2014
He is always attentive and willing to listen & help.
SHC Patient, Jan 2014
Utmost respect for Dr. Dorigo! Knowledgeable, caring, shows concern, genuine & thorough.